Results 31 to 40 of about 366,991 (303)

Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]

, 2009
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal, B Stordal, BK Stordal, H Kawai, H Kuroda, M Markman, S Henness, V Dieras   +7 more
core   +2 more sources

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Harreus, Ulrich, Reiter, Maximilian, Schwenk-Zieger, Sabina   +3 more
core   +1 more source

Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity

Redox Biology, 2016
Cisplatin-induced ototoxicity remains a primary dose-limiting adverse effect of this highly effective anticancer drug. The clinical utility of cisplatin could be enhanced if the signaling pathways that regulate the toxic side-effects are delineated.
Samson Jamesdaniel, Rajamani Rathinam, William L. Neumann   +2 more
doaj   +1 more source

Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer [PDF]

, 2010
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
Fujimoto, Nobukazu, Fujiwara, Yoshiro, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, Tanimoto, Mitsune, Toyooka, Shinichi, Ueoka, Hiroshi, Umemura, Shigeki   +8 more
core   +1 more source

PERBANDINGAN KEJADIAN LEUKOPENIA DAN TROMBOSITOPENIA PADA PENDERTIA KARSINOMA NASOFARING YANG MENDAPATKAN KEMOTERAPI PACLITAXEL CISPLATIN DAN CISPLATIN 5-FLUOROURACIL (5-FU)

Jurnal Kedokteran Diponegoro, 2019
Latar Belakang : Karsinoma Nasofaring (KNF) merupakan karsinoma yang muncul pada daerah nasofaring. Kemoterapi adalah segolongan obat-obatan yang dapat menghambat pertumbuhan kanker atau bahkan membunuh sel kanker.
Nadya Tara Audina, Willy Yusmawan, Zulfikar Naftali, Suprihati Suprihati   +3 more
doaj   +1 more source

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Alsubhi, N, Arora, A, Ball, G, Caldas, C, Chan, S, Doherty, R, Ellis, IO, Green, A, Madhusudan, S, Moseley, P, Perry, C, Rakha, EA, Russell, R, Seedhouse, C   +16 more
core   +1 more source

Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage

Clinical and Translational Science, 2023
Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods.
Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa‐Ishizawa, Kenta Yagi, Fuka Aizawa, Koji Miyata, Takahiro Niimura, Hirofumi Hamano, Takumi Sakurada, Yoshito Zamami, Keisuke Ishizawa   +13 more
doaj   +1 more source

MutS homologue hMSH5: role in cisplatin-induced DNA damage response

Molecular Cancer, 2012
Background Cisplatin (cis-diamminedichloroplatinum (II), CDDP) and its analogues constitute an important class of anticancer drugs in the treatment of various malignancies; however, its effectiveness is frequently affected by mutations in genes involved ...
Tompkins Joshua D, Wu Xiling, Her Chengtao   +2 more
doaj   +1 more source

Synergistic Effect of Anethole and Platinum Drug Cisplatin against Oral Cancer Cell Growth and Migration by Inhibiting MAPKase, Beta-Catenin, and NF-κB Pathways

Pharmaceuticals, 2023
Cisplatin is a common drug used to treat patients with oral squamous cell carcinoma. However, cisplatin-induced chemoresistance poses a major challenge to its clinical application.
Abdelhabib Semlali, Ikram Ajala, Sarra Beji, Mohammed Mousa Al-Zharani, Mahmoud Rouabhia   +4 more
doaj   +1 more source

Expression signatures of cisplatin- and trametinib-treated early-stage medaka melanomas [PDF]

, 2019
Small aquarium fish models provide useful systems not only for a better understanding of the molecular basis of many human diseases, but also for first-line screening to identify new drug candidates.
Boswell, William, Klotz, Barbara, Kneitz, Susanne, Lu, Yuan, Postlethwait, John, Shartl, Manfred, Walter, Ronald B, Warren, Wesley   +7 more
core   +2 more sources